Literature DB >> 8300060

Coping and satisfaction with growth hormone treatment among short-stature children.

E Leiberman1, D Pilpel, C A Carel, E Levi, Z Zadik.   

Abstract

The ability of children to cope with a chronic medical problem requiring prolonged treatment has an effect on the quality of life of these children and of their parents and serves as an index of the quality of treatment. This study deals with coping ability and satisfaction with treatment of children whose stature was two or more SD below the average for age and gender. The study population included 96 patients, 53 of whom were male, who were on growth hormone (GH) treatment for at least 1 year. 65 patients were without any underlying disease, 15 had classical GH deficiency and 16 had Turner syndrome or renal disease. All patients were treated with daily injections at home from 12 to 66 months. Using a self-administered questionnaire, the ability to cope and the degree of satisfaction and compliance with treatment were assessed. No significant differences were found with respect to gender, the presence of an underlying disease, age at which treatment commenced or duration of treatment. Despite the fact that the outcome of GH treatment on final height has yet to be established, satisfaction and compliance were high.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8300060     DOI: 10.1159/000183781

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  8 in total

Review 1.  Growing up with idiopathic short stature: psychosocial development and hormone treatment; a critical review.

Authors:  H Visser-van Balen; G Sinnema; R Geenen
Journal:  Arch Dis Child       Date:  2006-05       Impact factor: 3.791

2.  Hospitalized patients' satisfaction with caregivers' conduct and physical surroundings.

Authors:  D Pilpel
Journal:  J Gen Intern Med       Date:  1996-05       Impact factor: 5.128

3.  First-year predictors of health-related quality of life changes in short-statured children treated with human growth hormone.

Authors:  J Quitmann; J Bloemeke; H-G Dörr; M Bullinger; S Witt; N Silva
Journal:  J Endocrinol Invest       Date:  2019-03-06       Impact factor: 4.256

4.  Behavioral evaluation of GH treatment in short statured children and adolescents: findings from a pilot study.

Authors:  H C Steinhausen; H G Dörr; Z Malin
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

Review 5.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

6.  COMPLIA: A 12-MONTH PROSPECTIVE, MULTICENTRE, NON-INTERVENTIONAL STUDY TO EVALUATE TREATMENT ADHERENCE AND TREATMENT SATISFACTION IN A GROWTH HORMONE DEFICIENT PAEDIATRIC POPULATION TREATED WITH NUTROPINAQ® A SOMATROPIN ANALOGUE.

Authors:  C P Dumitrescu; C Procopiuc; N Dumitriu; I Micle; M Anton; A Moisuc
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

7.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2020-05-28

8.  Assessment of Psychosocial Status among Short-stature Children with and without Growth Hormone Therapy and Their Parents.

Authors:  Yasuhiro Naiki; Reiko Horikawa; Toshiaki Tanaka
Journal:  Clin Pediatr Endocrinol       Date:  2013-04-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.